Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02392234




Registration number
NCT02392234
Ethics application status
Date submitted
12/03/2015
Date registered
18/03/2015
Date last updated
12/06/2018

Titles & IDs
Public title
A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function
Secondary ID [1] 0 0
2014-004788-18
Secondary ID [2] 0 0
VX14-661-108
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cystic Fibrosis 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Cystic fibrosis
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - VX-661/Ivacaftor
Treatment: Drugs - Ivacaftor
Treatment: Drugs - Placebo matched to VX-661/ ivacaftor
Treatment: Drugs - Placebo matched to Ivacaftor

Experimental: VX-661/Ivacaftor combination -

Experimental: Ivacaftor monotherapy -

Placebo Comparator: Placebo -


Treatment: Drugs: VX-661/Ivacaftor
Fixed dose combination tablet, oral use

Treatment: Drugs: Ivacaftor
Tablet, oral use

Treatment: Drugs: Placebo matched to VX-661/ ivacaftor
Fixed dose combination tablet, oral use

Treatment: Drugs: Placebo matched to Ivacaftor
Tablet, oral use
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Week 4 and Week 8
Timepoint [1] 0 0
Baseline, Week 4 and Week 8 of each treatment period
Secondary outcome [1] 0 0
Absolute Change From Study Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Week 4 and Week 8
Timepoint [1] 0 0
Baseline, Week 4 and Week 8 of each treatment period
Secondary outcome [2] 0 0
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timepoint [2] 0 0
Day 1 up to Week 28
Secondary outcome [3] 0 0
Relative Change From Study Baseline in ppFEV1 at Average of Week 4 and Week 8
Timepoint [3] 0 0
Baseline, Week 4 and Week 8 of each treatment period
Secondary outcome [4] 0 0
Absolute Change From Study Baseline in Sweat Chloride at Average of Week 4 and Week 8
Timepoint [4] 0 0
Baseline, Week 4 and Week 8 of each treatment period
Secondary outcome [5] 0 0
Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1 VX-661), IVA and IVA Metabolite (M1 IVA) After Administration of VX-661/IVA Combination Therapy
Timepoint [5] 0 0
Pre-morning dose on Week 8 of each treatment period
Secondary outcome [6] 0 0
Ctrough of IVA and IVA Metabolite (M1 IVA) After Administration of IVA Monotherapy
Timepoint [6] 0 0
Pre-morning dose on Week 8 of each treatment period

Eligibility
Key inclusion criteria
- Heterozygous for F508del-CFTR and a second allele with a CFTR mutation predicted to
have residual function

- Forced Expiratory Volume in 1 Second (FEV1) greater than or equal to (=) 40 percent
(%) and less than or equal to (=) 90% of predicted normal for age, sex, and height
during screening

- Sweat chloride value =60 millimole per liter (mmol/L) during screening OR as
documented in the participant's medical record

- Stable CF disease as judged by the investigator
Minimum age
12 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- History of any comorbidity that, in the opinion of the investigator, might confound
the results of the study or pose an additional risk in administering study drug to the
participant

- An acute upper or lower respiratory infection, pulmonary exacerbation

- History of solid organ or hematological transplantation

- Ongoing or prior participation in an investigational drug study (including studies
investigating VX-661, lumacaftor [VX-809], and/or ivacaftor) within 30 days of
screening

- Pregnant and nursing females

- Sexually active participants of reproductive potential who are not willing to follow
the contraception requirements

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2017
Sample size
Target
Accrual to date
Final
248
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Adelaide
Recruitment hospital [2] 0 0
- Melbourne
Recruitment hospital [3] 0 0
- South Brisbane
Recruitment hospital [4] 0 0
- Westmead
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Melbourne
Recruitment postcode(s) [3] 0 0
- South Brisbane
Recruitment postcode(s) [4] 0 0
- Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
New Hampshire
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
South Dakota
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Utah
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
United States of America
State/province [27] 0 0
Wisconsin
Country [28] 0 0
Belgium
State/province [28] 0 0
Gent
Country [29] 0 0
Canada
State/province [29] 0 0
Montreal
Country [30] 0 0
Canada
State/province [30] 0 0
Quebec City
Country [31] 0 0
Canada
State/province [31] 0 0
Toronto
Country [32] 0 0
Canada
State/province [32] 0 0
Vancouver
Country [33] 0 0
France
State/province [33] 0 0
Bouches-du-Rhone
Country [34] 0 0
France
State/province [34] 0 0
Herault
Country [35] 0 0
France
State/province [35] 0 0
Ille Et Vilaine
Country [36] 0 0
France
State/province [36] 0 0
Nord
Country [37] 0 0
France
State/province [37] 0 0
Paris
Country [38] 0 0
France
State/province [38] 0 0
Rhone
Country [39] 0 0
France
State/province [39] 0 0
Bordeaux Cedex
Country [40] 0 0
Germany
State/province [40] 0 0
Bayern
Country [41] 0 0
Germany
State/province [41] 0 0
Niedersachsen
Country [42] 0 0
Germany
State/province [42] 0 0
Nordrhein Westfalen
Country [43] 0 0
Germany
State/province [43] 0 0
Thueringen
Country [44] 0 0
Germany
State/province [44] 0 0
Berlin
Country [45] 0 0
Israel
State/province [45] 0 0
Haifa
Country [46] 0 0
Israel
State/province [46] 0 0
Jerusalem
Country [47] 0 0
Israel
State/province [47] 0 0
Petach-Tikva
Country [48] 0 0
Israel
State/province [48] 0 0
Ramat-Gan
Country [49] 0 0
Italy
State/province [49] 0 0
Ancona
Country [50] 0 0
Italy
State/province [50] 0 0
Milano
Country [51] 0 0
Italy
State/province [51] 0 0
Orbassano
Country [52] 0 0
Italy
State/province [52] 0 0
Potenza
Country [53] 0 0
Italy
State/province [53] 0 0
Roma
Country [54] 0 0
Italy
State/province [54] 0 0
Verona
Country [55] 0 0
Netherlands
State/province [55] 0 0
Amsterdam
Country [56] 0 0
Netherlands
State/province [56] 0 0
Den Haag
Country [57] 0 0
Netherlands
State/province [57] 0 0
Rotterdam
Country [58] 0 0
Netherlands
State/province [58] 0 0
Utrecht
Country [59] 0 0
Switzerland
State/province [59] 0 0
Bern
Country [60] 0 0
Switzerland
State/province [60] 0 0
St Gallen
Country [61] 0 0
Switzerland
State/province [61] 0 0
Zuerich
Country [62] 0 0
United Kingdom
State/province [62] 0 0
Devon
Country [63] 0 0
United Kingdom
State/province [63] 0 0
Greater London
Country [64] 0 0
United Kingdom
State/province [64] 0 0
Greater Manchester
Country [65] 0 0
United Kingdom
State/province [65] 0 0
Hampshire
Country [66] 0 0
United Kingdom
State/province [66] 0 0
Lancashire
Country [67] 0 0
United Kingdom
State/province [67] 0 0
Strathclyde
Country [68] 0 0
United Kingdom
State/province [68] 0 0
West Yorkshire

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Vertex Pharmaceuticals Incorporated
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy and safety of VX-661 in combination
with ivacaftor (IVA, VX-770) and IVA monotherapy in participants with Cystic Fibrosis (CF)
who are heterozygous for F508del-CFTR allele and a second allele with a CFTR mutation
predicted to have residual function.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02392234
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02392234